Superworth

Acumen Pharmaceuticals price to book ratio ABOS

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
0.5×
5-year median
0.9×
Against its 5-year history
12th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.3× to 4.0×
Peer median
1.5×

Acumen Pharmaceuticals' price to book ratio is 0.5× as of Nov 2, 2026.

That is below its 5-year median of 0.9×, lower than on 88% of days in the last 5 years.

Over that time it ranged from 0.3× in Apr 2025 to 4.0× in Sep 2026.

The median for 7 healthcare stocks of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.5×0.4×4.0×
20251.4×0.3×1.4×
20240.5×0.5×1.0×
20230.8×0.5×2.4×
20221.1×0.6×2.0×
20211.2×1.2×1.7×

Against its peers

Companies in Healthcare nearest Acumen Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ABOSAcumen Pharmaceuticals0.5×
NEPHNephros2.9×
ATNMActinium Pharmaceuticals1.5×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage2.2×
ICCCImmucell3.1×
KEQUKewaunee Scientific1.3×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Acumen Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.